Day: September 2, 2021

FARMINGDALE, N.Y., Sept. 02, 2021 (GLOBE NEWSWIRE) — Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today reported unaudited financial results for the fiscal 2021 fourth quarter and full fiscal year ended June 30, 2021 as summarized below:  Three Months Ended   Years Ended    June 30,   June 30,      2021       2020       2021     2020                   Revenue $ 19,685,141     $ 13,713,231     $ 74,024,073   $ 62,483,651    Gross profit $ 14,075,377     $ 9,432,383     $ 52,636,255   $ 43,709,483    Gross profit percentage   71.5 %     68.8 %     71.1 %   70.0 %  Pretax loss $ (4,341,201 )   $ (8,495,994 )   $ (14,341,254 ) $ (21,916,952 )  Income tax expense (benefit) $ 132,071     $ 41,422     $ 132,071   $ (4,498,578 )  Net...

Net sales of $496.9 million, a total comparable sales growth of 8.1% on a two-year basis Continued margin expansion driving gross profit dollar growth of 17.8% on a two-year basis Net income of $5.2 million or an increase of $173.0 million compared to the second quarter of fiscal 2020 Adjusted EBITDA of $23.5 million or an increase of $27.8 million compared to the second quarter of fiscal 2020HUDSON, Ohio, Sept. 02, 2021 (GLOBE NEWSWIRE) — JOANN Inc. (NASDAQ: JOAN) (“JOANN”), the nation’s category leader in sewing and one of the fastest growing competitors in the arts and crafts category, today reported results for its second quarter ending July 31, 2021. Wade Miquelon, JOANN’s President and Chief Executive Officer stated, “We achieved a number of important milestones in our first full quarter as a newly public company. We...

Solid Net Sales Growth Realized Across All Operating Segments Strong Balance Sheet Liquidity Continues to Increase Repaid $15 Million of Bank Debt HOUSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) — Quanex Building Products Corporation (NYSE:NX) (“Quanex” or the “Company”) today announced its results for the three months ended July 31, 2021. The Company reported the following selected financial results:QUANEX BUILDING PRODUCTS CORPORATION                Q3 2021 Earnings Release                        Three Months Ended July 31,   Nine Months Ended July 31,($ in millions, except per share data)     2021   2020   2021   2020Net Sales     $279.9   $212.1   $780.4   $596.2Gross Margin     $60.0   $49.7   $175.7   $126.6Gross Margin %     21.4%   23.4%   22.5%   21.2%Net Income     $13.6   $10.8   $36.0   $16.3Diluted...

SAN RAMON, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) — CooperCompanies (NYSE: COO) today announced financial results for its fiscal third quarter ended July 31, 2021.Revenue increased 32% year-over-year to $763.4 million. CooperVision (CVI) revenue up 24% to $557.5 million, and CooperSurgical (CSI) revenue up 60% to $205.9 million. GAAP diluted earnings per share $12.37, up $11.25 from last year’s third quarter. Non-GAAP diluted earnings per share $3.41, up $1.13 or 50% from last year’s third quarter. See “Reconciliation of Selected GAAP Results to Non-GAAP Results” below.Commenting on the results, Al White, Cooper’s President and CEO said, “I am pleased to report another strong quarter with record revenues at both CooperVision and CooperSurgical driving record earnings and robust free cash...

Record second quarter sales exceeded high end of revenue guidance range Record second quarter GAAP EPS of $3.05 and adjusted EPS of $3.24 exceeded high end of earnings guidance range Raises full-year EPS guidance to $6.03 – $6.28 on a GAAP basis and $6.45 – $6.70 on an adjusted basisATLANTA, Sept. 02, 2021 (GLOBE NEWSWIRE) — Oxford Industries, Inc. (NYSE:OXM) today announced financial results for its fiscal 2021 second quarter ended July 31, 2021. Due to the material impact of COVID-19 on the Company’s business in fiscal 2020, this release includes comparisons of fiscal 2021 results to both fiscal 2019 and fiscal 2020. Consolidated net sales in the second quarter of fiscal 2021 were $329 million compared to $192 million and $302 million in the second quarters of fiscal 2020 and fiscal 2019, respectively. Earnings...

Completed upsized initial public offering of common stock, raising $349.6 million in gross proceeds including full exercise of underwriters’ option to purchase additional shares ANTLER Phase 1 clinical trial of CB-010 in relapsed or refractory B cell non-Hodgkin lymphoma ongoing Expanded company’s board of directors with appointment of Nancy Whiting, Pharm.D. BERKELEY, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported business highlights and financial results for the second quarter of 2021. “2021 has been a transformational year for Caribou, and we believe that our highly successful IPO speaks to the enormous potential of the company’s chRDNA technology to deliver innovative, transformative therapies for patients...

FREMONT, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) — Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB) today reported financial results for the second quarter ended June 30, 2021. Recent HighlightsRevenue was $30.4 million for the second quarter, representing a 59% increase over the second quarter of 2020 Expanded the installed base to 855 instruments, with 104 instrument placements during the second quarter Launched the Cytek Aurora Cell Sorter (CS), a high-dimensional benchtop cell sorter that delivers high resolution single-cell capabilities regardless of assay complexity or autofluorescence level Launched the Automated Sample Loader, an integrated plate and tube loader that streamlines the sample loading process – offering ‘walk away’ capabilities and expanding high-throughput acquisition options for...